Premium
P2–401: In vivo Gd‐staining MRI reveals efficacy of anti‐beta‐amyloid immunotherapy after longitudinal study in a transgenic mouse model of Alzheimer's disease
Author(s) -
Santin Mathieu,
Debeir Thomas,
Delzescaux Thierry,
Hérard AnneSophie,
Cohen Caroline,
Pradier Laurent,
Rooney Thomas,
Dhenain Marc
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1051
Subject(s) - in vivo , genetically modified mouse , medicine , antibody , pathology , staining , magnetic resonance imaging , amyloid (mycology) , immunohistochemistry , transgene , chemistry , immunology , biology , radiology , biochemistry , microbiology and biotechnology , gene
Fig. 1. Longit Left In vivo month-old. W Spots identifie into the ROIs. months. Right mice treated w bars stand for OFANTI-BETA-AMYLOID IMMUNOTHERAPY AFTER LONGITUDINAL STUDY IN ATRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE Mathieu Santin, Thomas Debeir, Thierry Delzescaux, AnneSophie H erard, Caroline Cohen, Laurent Pradier, Thomas Rooney, Marc Dhenain, URA CEA CNRS 2210, Fontenay aux Roses, France; Sanofi-Aventis, Chilly-Mazarin, France; Sanofi, Chily Mazarin, France; Sanofi, Chilly-Mazarin, France; CNRS, Fontenay-aux-Roses, France. Contact e-mail: Marc.Dhenain@cea.fr